个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共16条记录   Sigma-1 Receptor Agonists as Therapeutic Drugs for Cognitive Impairment in Neuropsychiatric Diseases [作者：Niitsu, T; Iyo, M; Hashimoto, K,期刊：Current Pharmaceutical Design, 页码：875-883 , 文章类型： Review，,卷期：2012年18-7] Cognitive impairment is a core feature of patients with neuropsychiatric diseases such as schizophrenia and psychotic depression. The drugs currently used to treat cognitive impairment have significant limitations, ensur... The Therapeutic Potential of Sigma (sigma) Receptors for the Treatment of Central Nervous System Diseases: Evaluation of the Evidence [作者：Banister, SD; Kassiou, M,期刊：Current Pharmaceutical Design, 页码：884-901 , 文章类型： Review，,卷期：2012年18-7] Since their proposal in 1976, sigma (sigma) receptors have been increasingly implicated in the pathophysiology of virtually all major central nervous system (CNS) disorders, including anxiety, depression, schizophrenia, ... Sigma-1 Receptors: Potential Targets for the Treatment of Substance Abuse [作者：Robson, MJ; Noorbakhsh, B; Seminerio, MJ; Matsumoto, RR,期刊：Current Pharmaceutical Design, 页码：902-919 , 文章类型： Review，,卷期：2012年18-7] Drug abuse is currently a large economic and societal burden in countries around the globe. Many drugs of abuse currently lack adequate therapies aimed at treating both the addiction and negative complications often asso... The Ligand Binding Region of the Sigma-1 Receptor: Studies Utilizing Photoaffinity Probes, Sphingosine and N-Alkylamines [作者：Ruoho, AE; Chu, UB; Ramachandran, S; Fontanilla, D; Mavlyutov, T; Hajipour, AR,期刊：Current Pharmaceutical Design, 页码：920-929 , 文章类型： Review，,卷期：2012年18-7] The sigma-1 receptor is a 26 kDa endoplasmic reticulum resident membrane protein that has been shown to have chaperone activity in addition to its promiscuous binding to pharmacological agents. Ligand binding domain(s) o... Pharmacophore Models and Development of Spirocyclic Ligands for sigma(1) Receptors [作者：Wunsch, B,期刊：Current Pharmaceutical Design, 页码：930-937 , 文章类型： Review，,卷期：2012年18-7] The existing pharmacophore models for sigma(1) receptor ligands are summarized. A common feature of these models is a basic amino group surrounded by different hydrophobic structural elements. The development of novel sp... Classes of Sigma(2) (sigma(2)) Receptor Ligands: Structure Affinity Relationship (SAfiR) Studies and Antiproliferative Activity [作者：Abate, C; Perrone, R; Berardi, F,期刊：Current Pharmaceutical Design, 页码：938-949 , 文章类型： Review，,卷期：2012年18-7] Although several pieces of information are still missing about sigma-2 (sigma(2)) receptor, the production of high affinity sigma(2) receptor ligands allowed important acquisitions. Morphans such as CB64D and CB184 were ... Inhibition of the Renin-Angiotensin-Aldosterone System: How to Obtain This [作者：Pende, A; Montecucco, F,期刊：Current Pharmaceutical Design, 页码：950-951 , 文章类型： Editorial Material，,卷期：2012年18-7] Combinations of Renin-Angiotensin-Aldosterone System Antagonists: True Advantages? [作者：Veglio, F; Puglisi, E; Milan, A; Mulatero, P,期刊：Current Pharmaceutical Design, 页码：952-957 , 文章类型： Review，,卷期：2012年18-7] The renin angiotensin aldosterone system (RAAS) inhibitors induce an incomplete blockade of the system at different steps. Recently, the dual RAAS therapy is emerging in clinical practice, although there is a lack of evi... Renin-Angiotensin-Aldosterone System Antagonists and the Prevention of Type 2 Diabetes Mellitus [作者：Stohr, R; Marx, N,期刊：Current Pharmaceutical Design, 页码：958-962 , 文章类型： Review，,卷期：2012年18-7] ACE inhibitors have established their role in the management of hypertension as well as in the primary and secondary prevention of cardiovascular events. Furthermore, they have proven their role in delaying the worsening... Role of Renin-Angiotensin System in Inflammation, Immunity and Aging [作者：Capettini, LSA; Montecucco, F; Mach, F; Stergiopulos, N; Santos, RAS; da Silva, RF,期刊：Current Pharmaceutical Design, 页码：963-970 , 文章类型： Review，,卷期：2012年18-7] Recent data support the idea that the effects of RAS are not restricted to the cardiovascular and renal systems. Importantly, RAS modulates free radical production and the cellular synthesis of several molecules such as ... RAAS Inhibition and Renal Protection [作者：Giovanna, L; Francesca, V; Roberto, P,期刊：Current Pharmaceutical Design, 页码：971-980 , 文章类型： Review，,卷期：2012年18-7] Chronic kidney disease has become a major public health problem worldwide mainly as a consequence of the emerging epidemic of hypertension, diabetes, and obesity. It is currently estimated that nearly 15% of the general ... Role of the Renin-Angiotensin-Aldosterone System in the Pathogenesis of Atherosclerosis [作者：Durante, A; Peretto, G; Laricchia, A; Ancona, F; Spartera, M; Mangieri, A; Cianflone, D,期刊：Current Pharmaceutical Design, 页码：981-1004 , 文章类型： Review，,卷期：2012年18-7] Renin-Angiotensin-Aldosterone (RAAS) is a hormone system which acts on multiple physiologic pathways primarily by regulating blood pressure and fluid balance, but also by local autocrine and paracrine actions. In pathoph... Vaccination Against High Blood Pressure [作者：Campbell, DJ,期刊：Current Pharmaceutical Design, 页码：1005-1010 , 文章类型： Review，,卷期：2012年18-7] Despite the attractiveness of a vaccination strategy for the treatment of high blood pressure, and many decades of research, attempts to translate this strategy to hypertension management have been unsuccessful. Immuniza... Renin-Angiotensin Antagonists: Therapeutic Effects Beyond Blood Pressure Control? [作者：Pende, A; Dallegri, F,期刊：Current Pharmaceutical Design, 页码：1011-1020 , 文章类型： Review，,卷期：2012年18-7] Guidelines for the treatment of hypertension allow a wide range of choices to the physicians; however some differences are present about the preferred drugs to start treatment. The most important aim remains an adequate ... Sigma Receptor Research: Progress Towards Diagnostic and Therapeutic Uses of Sigma Ligands [作者：Abate, C,期刊：Current Pharmaceutical Design, 页码：861-862 , 文章类型： Editorial Material，,卷期：2012年18-7] Pharmacology of Sigma (sigma) Receptor Ligands from a Behavioral Perspective [作者：Skuza, G,期刊：Current Pharmaceutical Design, 页码：863-874 , 文章类型： Review，,卷期：2012年18-7] The sigma receptors are regarded as unique binding sites, distinct from opiate and PCP receptors and implicated in higher brain function. They were classified into sigma(1) and sigma(2) subtypes, the former was cloned fr...